search
Back to results

Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation

Primary Purpose

Atrial Fibrillation

Status
Unknown status
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Epicardial fat biopsy
Sponsored by
Sheba Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Atrial Fibrillation focused on measuring Epicardial fat

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years
  • Undergoing an elective cardiac surgery

Exclusion Criteria:

  • Undergoing a non-elective surgery
  • Suffering from severe renal impairment prior to surgery (creatinine clearance <30 mL/min)
  • Experienced hepatic dysfunction other than mild

Sites / Locations

  • Sheba medical centerRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Atrial fibrillation

Control

Arm Description

An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery

An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery

Outcomes

Primary Outcome Measures

Exosomes quantity excreted from the epicardial fat (nm)
The differences in the quantity of exosomes derived epicardial fat in patients with and without atrial fibrillation. The exosome isolation will be done by using ultra centrifuge for cells and cells debris removal. Then the exosomes will examined by the Malvern NanoSight device both for particle size and concentration measurement.

Secondary Outcome Measures

Inflammatory cytokines secretion from epicardial fat
The differences in the Inflammatory cytokines secreted from epicardial fat in patients with and without atrial fibrillation. The investigators will detect the levels of cytokines and acute phase proteins such as IL1, IL2, IL6, IL8, IL10, IL12, CRP, VEGF, TNF-a, and TGF by Human Cytokine Array Kit.

Full Information

First Posted
March 20, 2018
Last Updated
April 6, 2021
Sponsor
Sheba Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03478410
Brief Title
Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation
Official Title
Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation
Study Type
Interventional

2. Study Status

Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 21, 2018 (Actual)
Primary Completion Date
January 21, 2022 (Anticipated)
Study Completion Date
January 21, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sheba Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Exosome plays an important role in the pathophysiology of the cardiovascular system. Since the field of cardiovascular exosome is still in its infancy, there are no available data regarding to its role in cardiac arrhythmias. The current study investigates the role of epicardial fat derived exosomes in patients who suffer from atrial fibrillation.
Detailed Description
Myocardial cells communication is mediated via direct cell to cell contact, cell to matrix interaction, long-range signals, electrical signals, and via extracellular chemical molecules (such as proteins, nucleotides, lipids and short peptides). Cell to cell communication can be achieved through direct contact (i.e. Gap junction, cell surface protein/protein interaction) or via secreted signaling molecules (i.e. hormones, neurotransmitters, cytokines). In the last few decades, a third intercellular communication mechanism has gained intense attention - extracellular vesicles that include: (1) apoptotic vesicles (1000-4000 nm), (2) microvesicles (100 nm - 1000 nm), and the smallest extracellular vesicles (3) exosomes (40-100 nm). The exosomes are produced through the endosomal pathway and are able to carry cargo and transfer them to recipient cells, thus contributing to cell-to-cell communication. The exosomes cargo includes protein content, rRNA, tRNA, short DNA sequences, messenger RNA (mRNA) and microRNA (miRNA). The last two can change the gene expression within the target cells and by that affect myocardial cells. Nowadays, it is known that in the cardiovascular system, exosome plays important roles in the pathophysiology of myocardial infarction (MI) and as an indicator for the damage and repair mechanisms post-acute MI (i.e. miR-126), in myocardial remodeling, and cardiac regeneration. Since the field of cardiovascular exosome is still in its infancy, there are no available data regarding to its role in cardiac arrhythmias. Therefore, there is place to investigate the role of exosomes in patients who suffer from atrial fibrillation. Some of the important issues to explore are: (1) Do the epicardial fat in patients with atrial fibrillation release quantitatively and qualitatively different exosomes than in patients without atrial fibrillation? (2) Can epicardial fat exosomes be a clinical biomarker for arrhythmias? (3) Can these exosomes be a target for the treatment and prevention of arrhythmias? The current study will include patients who undergo any cardiac surgery and will give informed consent. An epicardial fat biopsy will be taken and cultured in a medium that contain M-199 medium, dexamethasone, gentamicin, and insulin for 9 days. The exosomes will be collected from the medium and analyzed. The participants will be divided into two groups: (1) participants with atrial fibrillation, (2) participants who did not develop ever atrial fibrillation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
Epicardial fat

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Comparative study between patients with and without atrial fibrillation
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Atrial fibrillation
Arm Type
Other
Arm Description
An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
Arm Title
Control
Arm Type
Other
Arm Description
An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
Intervention Type
Procedure
Intervention Name(s)
Epicardial fat biopsy
Intervention Description
A 1 cm (~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
Primary Outcome Measure Information:
Title
Exosomes quantity excreted from the epicardial fat (nm)
Description
The differences in the quantity of exosomes derived epicardial fat in patients with and without atrial fibrillation. The exosome isolation will be done by using ultra centrifuge for cells and cells debris removal. Then the exosomes will examined by the Malvern NanoSight device both for particle size and concentration measurement.
Time Frame
9 days
Secondary Outcome Measure Information:
Title
Inflammatory cytokines secretion from epicardial fat
Description
The differences in the Inflammatory cytokines secreted from epicardial fat in patients with and without atrial fibrillation. The investigators will detect the levels of cytokines and acute phase proteins such as IL1, IL2, IL6, IL8, IL10, IL12, CRP, VEGF, TNF-a, and TGF by Human Cytokine Array Kit.
Time Frame
9 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Undergoing an elective cardiac surgery Exclusion Criteria: Undergoing a non-elective surgery Suffering from severe renal impairment prior to surgery (creatinine clearance <30 mL/min) Experienced hepatic dysfunction other than mild
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eilon Ram, MD
Phone
972-54-4929101
Email
eilon.ram@sheba.health.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Dina Kogan
Phone
972-52-8646402
Email
Diana.Kogan@sheba.health.gov.il
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eilon Ram, MD
Organizational Affiliation
Sheba Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sheba medical center
City
Ramat Gan
ZIP/Postal Code
52621
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Diana Kogan
Phone
972-52-8646402
Email
Diana.Kogan@sheba.health.gov.il
First Name & Middle Initial & Last Name & Degree
Eilon ram, MD
Phone
972-54-4929101
Email
eilon.ram@sheba.health.gov.il

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Results: The exosomes content in patients with and without atrial fibrillation

Learn more about this trial

Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation

We'll reach out to this number within 24 hrs